Clinical trials: Tace
Hepatocellular Carcinoma
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.
- Trial name
- NCT04635527
- Testing
- IBI318, cTACE
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
HCC
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06844357
- Testing
- tirapazamine, Transarterial Embolization (TAE), TACE
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Intrahepatic Cholangiocarcinoma
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.
- Trial name
- NCT04954781
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma
This Phase Ia study evaluated the safety and tolerability of a single escalating dose via intravenous infusion of the autologous invariant natural killer T cells (iNKT-cell) product GKL-006 in combination with transarterial…
- Trial name
- NCT07845266
- Testing
- GKL-006 Injection, transarterial chemoembolization
- Where
- 2 sites in China
- Volunteers
- 13 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Transcatheter Arterial Chemoembolization, Unresectable Hepatocellular Carcinoma
A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy
The entry point of this study is the proposition of "generative longitudinal prediction," which utilizes only pre-treatment imaging to create high-fidelity predictions of post-treatment imaging.
- Trial name
- NCT07065786
- Testing
- Generative model
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Zhongda Hospital
Carcinoma, Hepatocellular, Neoplastic Cells, Circulating
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
This study is designed to prospectively evaluate whether post-hepatectomy adjuvant transcatheter arterial chemoembolization (TACE) is effective in reducing early recurrence in HCC patients with preoperative CTC ≥2.
- Trial name
- NCT02631499
- Testing
- TACE, Epirubicin, lipiodol
- Where
- 6 sites in China
- Volunteers
- 256 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma (HCC), Cachexia
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
Primary Objective: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on body weight and appetite in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and…
- Conditions
- Hepatocellular Carcinoma (HCC), Cachexia, Anorexia, Malnutrition
- Trial name
- NCT07565415
- Testing
- Nanocrystalline megestrol acetate
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Systemic therapy is the primary option for managing advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab (A+B) has emerged as the first-choice treatment for advanced HCC(IM brave 150).
- Trial name
- NCT06199297
- Testing
- Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Carcinoma
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC.
- Trial name
- NCT06896396
- Testing
- Lenvatinib, Pembrolizumab, Icaritin soft capsules, TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhiyong Huang
Hepatocellular Carcinoma, Portal Hypertension
Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)
The purpose of this study is to discuss the prognostic value of CEPH among HCC patients underwent TACE treatment, its impact on overall survival, and try to stratify patient cohorts for a better treatment strategy.
- Trial name
- NCT05703750
- Testing
- TACE ± Systemic therapy
- Where
- 2 sites in China
- Volunteers
- 228 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
The application of transarterial chemoembolisation (TACE) with drug-eluting beads in patients with hepatocellular carcinoma and its response to the treatment will be observed.
- Trial name
- NCT04780789
- Testing
- Transarterial Chemoembolization
- Volunteers
- 61 people
- Sponsor
- Brno University Hospital
Clinically Significant Portal Hypertension
The Effect of Sorafenib on Portal Pressure
Sorafenib is approved by the US FDA for the treatment of unresectable (can not operate) liver cancer and for renal cell carcinoma.
- Trial name
- NCT01714609
- Testing
- Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Unresectable Intrahepatic Cholangiocarcinoma
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT04301778
- Testing
- Durvalumab, SNDX-6352
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Metastases, Endobronchial Metastases
Chemoembolization for Lung Tumors
This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.
- Conditions
- Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
- Trial name
- NCT04200417
- Testing
- Chemoembolization, Mitomycin C, Lipiodol
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Malignant Neoplasm
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection.
- Trial name
- NCT03575806
- Testing
- TACE plus autologous Tcm immunotherapy, TACE
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
BCLC Stage C Hepatocellular Carcinoma
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage.
- Trial name
- NCT04992143
- Testing
- TACE, Tilelizumab, Sorafenib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.
- Trial name
- NCT04387695
- Testing
- SBRT+TACE+Sorafenib, Sorafenib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Cancer, Metastatic Cancer
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases.
- Conditions
- Cancer, Metastatic Cancer, Liver Metastases
- Trial name
- NCT06311851
- Testing
- Bevacizumab
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Pardis Noor Medical Imaging and Cancer Center
Hepatocellular Carcinoma
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermediate-stage hepatocellular carcinoma (HCC)…
- Trial name
- NCT03791918
- Testing
- Lenvatinib, PD-1 antibody, TACE
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Cholangiocarcinoma
Liver Embolization Approaches for Tumor Management
The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Metastatic Colon Cancer, Metastatic Cancer
- Trial name
- LEATUM (NCT05714124)
- Testing
- Embolization
- Where
- Italy
- Volunteers
- 580 people
- Sponsor
- IRCCS San Raffaele